HopeStage
Back to all studies
CompletedNCT06664138

Remimazolam or etomidate before electroconvulsive therapy

About this titleRead the official source — NCT06664138
Medication studyAges 18–70South KoreaSchizophrenia
The study in practice

Understand this study

Who was this study for?

Listed age limits: 18 years to 70 years.

Listed locations
CheonanSee all locations and recruitment
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateStarted: April 28, 2023
Recruitment status
Completed
Enrollment listed in the registry
30
Sponsor
Yeongseok Yun
Sponsor type
Unknown or unclear
Study type
Drug
Intervention type
Drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
South Korea
Age range
From 18 Years to 70 Years
Official registry ID
NCT06664138
Official title
Show the full official title

Comparison of Remimazolam and Etomidate As Induction Agents for Electroconvulsive Treatment

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Cheonan

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Yeongseok Yun.

Did this study involve medication?

Yes. The study involved medication, including Remimazolam and Etomidate.

Who was this study for?

Listed age limits: 18 years to 70 years.

Want to explore more studies?

Explore studies